Renal Non-Clear Cell Carcinoma — Trials

Renal Non-Clear Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

71 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 37
Recruiting: 15
Ph III recruiting: 0
Growth YoY: —
Industry share: 19%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (4)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05252585	A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)	active not recruiting	Phase 4	4	Novartis PharmaceuticalsINDUSTRY	1	Sep 17, 2026	clinicaltrials
NCT03525834	Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.	completed	Phase 4	40	Novartis PharmaceuticalsINDUSTRY	1	Sep 9, 2021